These guys don't burn much money, only $185k in this qtr, still a decent $1.3m in hand.
Nice progress too, although a shame it has to wait til the quarterly to announce some of this stuff but hopefully now some of the "bigger" announcements will flow:
" To be completed in June Quarter:
1. Manufacture initial market testing quantities.
2. Australian product certification with NATA approved laboratory.
3. Initial market entry plan and place product with selected end users.
4. Refine Oraline 4 Moulds if necessary.
5. Print pouches, packaging and user guides.
6. Product soft launch.
7. Sign off on dual strip Oraline model drawings and produce 3D-printed prototype.
8. Test 3D-printed prototype of new model and make final modifications. "
I'm still looking forward to seeing what they can do on the side, especially given they have 1.3m in hand:
"The Company has previously stated its intention to investigate licensing or investment opportunities in
therapeutic applications. During the March quarter Sun Biomedical has engaged with several
Australian research institutions in the area of asthma and airway inflammation. The process has also
uncovered a number of other potential therapeutic areas, which may be suitable for consideration by
the board of the Company. "
- Forums
- ASX - By Stock
- latest announcement
These guys don't burn much money, only $185k in this qtr, still...
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SBN (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online